Report on clinical performance of the SARS-CoV-2 and influenza qcLAMP assays based on the IRIS device

400 patients samples will be used to evaluate the IRISbased detection assays already developed by FORTH partner using extracted RNA from patients samples 200 samples for COVID and 200 for flu using in each case 100 positive and 100 negative in order to perform a reliable statistical analysis that will be suitable for the certification process the above number of samples will be tested in each clinical site 800 samples in total